Higher Genotyping Performance of the Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit Against ViroSeq HIV-1 Genotyping Kit in HIV Protease, Reverse Transcriptase, and Integrase Regions
The TaqPath Kit demonstrated higher genotyping performance compared to the ViroSeq assays. The TaqPath Kit was able to detect DRMs in the PR, RT and INI regions of various HIV-1 subtypes, offering a critical tool to identify and monitor HIV drug resistance to new and existing antiretroviral drugs targeting these regions.
Authors
- Simani Gaseitsiwe (ORCID: https://orcid.org/0000-0002-7089-3735)
- Obiageli Okafor (ORCID: https://orcid.org/0000-0002-8831-3399)
- Ontlametse T. Bareng (ORCID: https://orcid.org/0009-0005-8147-2193)
- Andrea Arias (ORCID: https://orcid.org/0000-0001-5777-3168)
- Wonderful Tatenda Choga (ORCID: https://orcid.org/0000-0001-7606-0569)
- Sikhulile M. Moyo (ORCID: https://orcid.org/0000-0003-3821-4592)
- Goitseone Martha Lemogang
- Gaonyadiwe Muzanywa
Institutions
- Harvard University (US)
- University of Botswana (BW)
- Stellenbosch University (ZA)
- Thermo Fisher Scientific (United States) (US)
- Botswana Harvard AIDS Institute Partnership (BW)
- University of Pretoria (ZA)
Publication Details
- Journal
- Infection and Drug Resistance
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/idr.s488722
- Primary Topic
- Genetics, Bioinformatics, and Biomedical Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bill and Melinda Gates Foundation
- European Commission
- National Institutes of Health
- Centers for Disease Control and Prevention
- Fogarty International Center
- Common Fund
- European and Developing Countries Clinical Trials Partnership